BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
/ 9 items
#IONS↓
Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.
Biogen Advances Alzheimer’s Drug Diranersen to Phase 3 After It Slashes Tau and Slows Cognitive Decline
Biogen’s diranersen showed robust tau reduction and slowed cognitive decline in early Alzheimer’s Phase 2 trial. Moving to late-stage studies despite missing primary endpoint.
Ionis’ Zilganersen Stabilizes Walking and Motor Skills in Alexander Disease Study
Ionis drug zilganersen showed promise for rare brain disease (Alexander disease), improving symptoms; FDA decision due Sept 2026.
GSK and Ionis Announce Major Win Against Hepatitis B in Landmark Trials
GSK and Ionis announce breakthrough results for bepirovirsen, a potential first-in-class treatment offering functional cure for chronic hepatitis B in just six months.
JPMorgan Boosts Ionis Stock Rating on Strong Drug Pipeline
JPMorgan analyst upgrades Ionis Pharmaceuticals to Overweight, raising price target to $80 from $49, citing strong drug launches and path to profitability.